类风湿关节炎患者停用托法替布后持续缓解(XANADU研究):一项开放标签随机研究
本研究纳入113例对甲氨蝶呤(MTX)应答不足的类风湿关节炎患者,随机分两组接受托法替布联合MTX治疗,第52周达到临床疾病活动指数缓解后分别停用托法替布或MTX。停用托法替布后仅29.2%(7/24)维持缓解,停用MTX后50.0%(10/20)维持缓解,差异无统计学意义;58%的参与者出现复发,复发者恢复托法替布后71.4%重新达到缓解。
要点
- 停用托法替布后仅29.2%(7/24)维持缓解,停用MTX后50.0%(10/20)维持缓解,差异无统计学意义。
- 58%的参与者出现复发,复发者恢复托法替布后71.4%重新达到缓解。
- 停用托法替布无严重不良事件;能停用托法替布且未复发者停药前类风湿因子较低(p=0.04)。
核心结论
- 作者认为全面停用托法替布可能不适合所有患者,因为58%的参与者出现复发。
- 作者认为停用托法替布不太可能导致治疗耐药。
研究设计与样本
- 开放标签随机研究,纳入对MTX应答不足(合用或未合用生物改善病情抗风湿药)的类风湿关节炎患者,基线随机分两组,均接受托法替布联合MTX治疗。
- 第52周达到临床疾病活动指数缓解者分别停用MTX或托法替布,主要结局为第104周维持临床缓解的比例。
- 共113例患者参与,其中48例在第52周达到缓解。
主要发现
- 停用托法替布后仅29.2%(7/24)维持缓解,停用MTX后50.0%(10/20)维持缓解,数值上较高但无统计学显著差异。
- 未用过生物制剂的患者在第52周达到缓解及第104周停用托法替布后维持低疾病活动度的比例更高。
- 能停用托法替布且未复发者停药前类风湿因子较低(p=0.04),抗环瓜氨酸肽抗体较低(p=0.051)。
- 停用托法替布或MTX后未记录到严重不良事件;停用托法替布后复发者中71.4%恢复托法替布后达到缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis. METHODS: Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying antirheumatic drugs were randomly divided into two groups at baseline, and tofacitinib treatment in combination with MTX was administered to both groups. Either MTX or tofacitinib was then withdrawn if patients achieved Clinical Disease Activity Index remission at week 52. The primary outcome was the proportion of patients who sustained clinical remission at week 104. RESULTS: A total of 113 patients participated in this study. Among them, a total of 48 patients achieved remission at week 52. After discontinuation of tofacitinib, only 29.2% (7/24) of patients remained remission, while 50.0% (10/20) of patients, which was numerically higher but not statistically significant, sustained remission after MTX discontinuation. A greater proportion of bio-naïve patients achieved remission at week 52 and sustained low disease activity with tofacitinib discontinuation at week 104. Additionally, the patients who were able to discontinue tofacitinib without flares had lower rheumatoid factor (p=0.04) and lower anti-cyclic citrullinated peptide antibody (p=0.051) before discontinuation of tofacitinib. No severe adverse events were recorded after discontinuation of tofacitinib or MTX. In patients who relapsed after tofacitinib discontinuation, 71.4% achieved remission with resumption of tofacitinib. CONCLUSIONS: This study implies that a blanket cessation of tofacitinib may not be suitable for all patients, given that 58% of the participants experienced relapse. However, the withdrawal of tofacitinib is unlikely to result in the acquisition of treatment-resistance.
引用
- Kubo S, Miyazaki Y, Amano K, et al. Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study. RMD Open. 2023. PMID: 37185309. doi:10.1136/rmdopen-2023-003029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。